The Dementia Discovery Fund (DDF), a SV Health Investors (SV) fund specialized in pursuing transformational therapeutic approaches for dementias including ...
Serina Therapeutics, Inc. (Serina), a privately held, clinical stage biotechnology company focused on developing its proprietary POZ Platform TMdrug delive...
Cytiva, a global leader in life sciences, introduces the innovative Cytiva Protein Select technology, designed to streamline and accelerate recombinant pro...
The deal with Novartis seeks to advance Legend Biotech’s autologous CAR-T cell therapy candidate, LB2102, and other potential CAR-T cell therapies ...
Investment of EUR 175 million reaffirms Sandoz commitment to long-term leadership in off-patent medicines New penicillin production process will signifi...
Positive CHMP opinion for Uzpruvo biosimilar is based on comprehensive package comprising analytical, non-clinical and clinical similarity data, includin...
– Celest to lead clinical development with technical support from Senti Bio – – First patient expected to be enrolled in China in 1H 202...
First placebo-controlled randomized trial in active psoriatic arthritis (PsA) using a Nanobody® to report positive topline results in support of pote...
Novogene is a leading provider of genomic services and solutions offering extensive next generation sequencing (NGS) capacity and bioinformatics expertise....
Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a new generation of its distributed liquid bi...
Adds to robust offering of NGS tools enabling exome sequencing, whole genome sequencing, RNA sequencing and methylation detection Enables multiplexing and...
Funds to support translation of R&D programs derived from proprietary NetMAPPR machine learning network biology platform and CombiGEM combinatorial gen...
Adult patients with: moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy; active psoriatic arthritis; moderate...
Collaboration to develop, manufacture and commercialize next-generation selective PARP1 inhibitor HRS-1167, with option to develop, manufacture and comme...
© 2024 Biopharma Boardroom. All Rights Reserved.
